Twelve-month follow-up data from a clinical trial of OrbusNeich's Genous stent has revealed that the device is safe and effective.
The Genous stent is an endothelial progenitor cell capture technology that enhances the natural healing of the vessel wall.
The multi-centre prospective clinical study, called e-HEALING, included 4,939 patients with at least one lesion suitable for non-urgent percutaneous coronary intervention.
Target vessel failure occurred in 11.7% of patients over the age of 75, in 8.8% of patients between the ages of 65 and 74, and in 7% of patients younger than 65.
Secondary endpoint includes composite of cardiac death, myocardial infarction and the target lesion revascularization rate.